Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series

Am J Hematol. 2021 Dec 1;96(12):E461-E463. doi: 10.1002/ajh.26365. Epub 2021 Oct 9.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Fecal Microbiota Transplantation*
  • Female
  • Graft vs Host Disease / therapy*
  • Humans
  • Janus Kinases / antagonists & inhibitors
  • Male
  • Middle Aged
  • Nitriles / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Steroids / therapeutic use

Substances

  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Steroids
  • ruxolitinib
  • Janus Kinases